Therefore, the combination of IDH inhibitors and DNA methyltransferase (DNMT) inhibitors (e.g. azacitidine) that can reduce DNA methylation is a promising regimen for the treatment of IDH-mutated AML patients. Here, IDH1 is linked to acute myeloid leukemia.